Emgality™ (galcanezumab-gnlm)

Emgality is a CGRP blocker approved for the prevention of migraine in adults. Emgality is manufactured by Eli Lilly and Company.

What is the ingredient in Emgality?

The active ingredient in Emgality is galcanezumab, a monoclonal antibody.

How does Emgality work?

Emgality is a monoclonal antibody that targets CGRP, binding to the protein and inhibiting its activity. CGRP (calcitonin gene-related peptide) is a newly identified protein that has been discovered as a key component in some migraine attacks. CGRP is considered a neurotransmitter (a chemical messenger) and is present throughout the brain and body. Researchers have found that levels of CGRP are higher during a migraine attack, which led to the development of products to block the protein.

What are the possible side effects of Emgality?

Some patients in clinical trials experienced a hypersensitivity (allergic reaction) to Emgality, which can cause rash, itching, difficulty breathing, and swelling of the mouth, lips, tongue, or throat. The most common side effects experienced by patients taking Emgality in clinical trials were injection site reactions, such as soreness and redness.

Things to know about Emgality

If a serious allergic reaction (hypersensitivity) occurs, patients should stop using Emgality. Treatment for the allergic reaction may be needed. Allergic reactions may occur days after the injection.

Dosing information

Emgality is a once-monthly injection that can be self-administered under the skin (subcutaneously). The recommended dose is an initial “loading” dose of 240 mg, given as two 120 mg injections, and a monthly maintenance dose of 120 mg.

For more information, read the full prescribing information for Emgality.

View References
Emgality prescribing information. Available at http://pi.lilly.com/us/emgality-uspi.pdf Accessed 10/10/18.